Incidence-based cost-of-illness model for metastatic breast cancer in the United States

International Journal of Technology Assessment in Health Care

Volumn 28, Issue 1, 2012, Pages 12-21

  Sorensen, Sonja V ^a   Goh, Jo Wern ^a   Pan, Feng ^a   Chen, Connie ^b   Yardley, Denise ^c   Martín, Miguel ^d   Knopf, Kevin ^a   Benedict, Ágnes ^a   Giorgetti, Carla ^b   Iyer, Shrividya ^b  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b PFIZER INC   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Cost of illness; Economic model; Lost productivity; Metastatic breast cancer

Indexed keywords

ADVERSE EVENTS; BREAST CANCER; CANCER THERAPY; COST-OF-ILLNESS; DISEASE MANAGEMENT; ECONOMIC MODEL; KEY MODELS; OVERALL SURVIVAL; PALLIATIVE CARE; SOCIETAL COSTS; TOTAL COSTS; TOTAL DISCOUNTED COST; UNIT COST; WAGE RATE;

CHEMICAL DETECTION; COMPUTER SIMULATION; COSTS; DIAGNOSIS; DISEASES; EMPLOYMENT; PATIENT TREATMENT; PRODUCTIVITY;

COST BENEFIT ANALYSIS;

CYCLOPHOSPHAMIDE; DOXORUBICIN; PACLITAXEL;

ABSENTEEISM; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER PALLIATIVE THERAPY; CANCER STAGING; CANCER THERAPY; CAREGIVER; FOLLOW UP; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; METASTASIS; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; SALARY; SIMULATION; TREATMENT OUTCOME; UNITED STATES;

ADULT; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEALTH CARE COSTS; HEALTH RESOURCES; HUMANS; INCIDENCE; MIDDLE AGED; NEOPLASM METASTASIS; PROGNOSIS; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES; YOUNG ADULT;

EID: 84859046226     PISSN: 02664623     EISSN: 14716348     Source Type: Journal    
DOI: 10.1017/S026646231100064X     Document Type: Article

References (28)

1. Allen JM. Economic/societal burden of metastatic breast cancer: A US perspective. Am J Manag Care. 2010;16:697-704.
2. Barron JJ, Quimbo R, Nikam PT, Amonkar MM. Assessing the economic burden of breast cancer in a US managed care population. Breast Cancer Res Treat. 2008;109:367-377. (Pubitemid 351644849)
3. Bennett CL, Calhoun EA. Evaluating the total costs of chemotherapyinduced febrile neutropenia: Results from a pilot study with community oncology cancer patients. Oncologist. 2007;12:478-483. (Pubitemid 46698725)
4. Berkowitz N, Gupta S, Silberman G. Estimates of the lifetime direct costs of treatment for metastatic breast cancer. Value Health. 2000;3:23-30. (Pubitemid 30232945)
5. Brewster AM, Hortobagyi GN, Broglio KR, et al. Residual risk of breast cancer recurrence 5 years after adjuVant therapy. J Natl Cancer Inst. 2008;100:1179-1183.
6. Bureau of Labor Statistics. News release: The employment situation - April 2011. Washington, DC: U.S. Department of Labor; 2011.
7. Bureau of Labor Statistics. Table 22: Persons at work in nonagricultural industries by age, sex, race, Hispanic or Latino ethnicity, marital status, and usual full- or part-time status. U.S. Department of Labor; 2010.
8. Bureau of Labor Statistics & U.S. Census Bureau. Current Population Survey, Design and Methodology. Technical Paper TP63RV. Washington, DC: U.S. Department of Labor and U.S. Department of Commerce, Economics and Statistics Administration; 2010.
9. Campbell JD, Ramsey SD. The costs of treating breast cancer in the US: A synthesis of published evidence. Pharmacoeconomics. 2009;27:199-209.
10. Davis KL, Iyer S, Candrilli S. Predictors of the direct costs of breast cancer in the United States elderly population. Value Health. 2010;13: A260.
11. Elting LS, Shih YC. The economic burden of supportive care of cancer patients. Support Care Cancer. 2004;12:219-226. (Pubitemid 38678556)
12. Hartmann LC, Zahasky KM, Grendahl DC. Management of cancer pain. Safe, adequate analgesia to improve quality of life. Postgrad Med. 2000;107:267-272, 75-76.
13. Hayman JA, LangaKM, KabetoMU, et al. Estimating the cost of informal caregiving for elderly patients with cancer. J Clin Oncol. 2001;19:3219-3225. (Pubitemid 32591439)
14. Kruse GB, Amonkar MM, Smith G, et al. Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. J Manag Care Pharm. 2008;14:844-857.
15. Kurian AW, Thompson RN, Gaw AF, et al. A cost-effectiveness analysis of adjuVant trastuzumab regimens in early HER2/neu-positive breast cancer. J Clin Oncol. 2007;25:634-641. (Pubitemid 350002917)
16. Lamerato L, Havstad S, Gandhi S, et al. Economic burden associated with breast cancer recurrence: Findings from a retrospective analysis of health system data. Cancer. 2006;106:1875-1882. (Pubitemid 43673201)
17. Mauri D, Polyzos NP, Salanti G, et al. Multiple-treatments meta-analysis of chemotherapy and targeted therapies in adVanced breast cancer. J Natl Cancer Inst. 2008;100:1780-1791.
18. Montazeri A. Health-related quality of life in breast cancer patients:A bibliographic review of the literature from 1974 to 2007. J Exp Clin Cancer Res. 2008;27:32.
19. National Cancer Institute. Cancer trends progress report - 2009/2010 uapdate. Bethesda, MD: NIH, DHHS; April 2010.
20. National Cancer Institute. Surveillance Epidemiology and End Results (SEER) - Breast cancer. 2007-2010. Bethesda, MD: National Cancer Institute.
21. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology. 2011. Fort Washington, PA: National Comprehensive Cancer Network.
22. Printz C. Healthcare reform affects cancer on many fronts. More coverage for treatment and prevention planned. Cancer. 2010;116:3525-3526.
23. Rao S, Kubisiak J, Gilden D. Cost of illness associated with metastatic breast cancer. Breast Cancer Res Treat. 2004;83:25-32. (Pubitemid 38141890)
24. Schwartz J. Current combination chemotherapy regimens for metastatic breast cancer. Am J Health Syst Pharm. 2009;66(Suppl 6):S3-S8.
25. Sloss EM, Wickstrom SL, McCaffrey DF, et al. Direct medical costs attributable to acute myocardial infarction and ischemic stroke in cohorts with atherosclerotic conditions. Cerebrovasc Dis. 2004;18:8-15. (Pubitemid 38823827)
26. Stokes ME, Thompson D, Montoya EL, et al. Ten-year survival and cost following breast cancer recurrence: Estimates from SEER-medicare data. Value Health. 2008;11:213-220. (Pubitemid 351473603)
27. Wang SJ, Fuller CD, Choi M, Thomas CR. A cost-effectiveness analysis of adjuVant chemoradiotherapy for resected gastric cancer. Gastrointest Cancer Res. 2008;2:57-63.
28. Yabroff KR, Lawrence WF, Clauser S, et al. Burden of illness in cancer survivors: Findings from a population-based national sample. J Natl Cancer Inst. 2004;96:1322-1330. (Pubitemid 39264121)